PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Discover Medical Devices

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Discover Medical Devices Announces Successful Intermediate Results of its SomnuSeal Trial - Discover Medical SomnuSeal masks are the first CPAP masks that successfully address the problem of non compliance in Sleep Apnea patients. 90% compliance among current users of traditional masks, 26% compliance among non compliant patients
Discover Medical Devices Announces Successful Intermediate Results of its SomnuSeal Trial

 

NewswireToday - /newswire/ - Givataym, Israel, 2012/02/27 - Discover Medical SomnuSeal masks are the first CPAP masks that successfully address the problem of non compliance in Sleep Apnea patients. 90% compliance among current users of traditional masks, 26% compliance among non compliant patients.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Discover Medical Devices SomnuSeal masks line are the first CPAP masks that successfully address the problem of non compliance in Obstructive Sleep Apnea patients. The revolutionary SomnuSeal mask has 90% compliance among current users of traditional masks and 26% compliance among non compliant OSA patients that refuse to use any traditional mask.
The novel SomnuSeal masks do not suffer from the side effects of traditional masks and therefore will allow many millions of OSA patients that currently refuse treatment to receive an effective treatment.

Eran Lavi, founder and CEO of Discover Medical Devices comments on the new clinical data: “Today more than 2 million patients are diagnosed each year as OSA patients that require CPAP treatment. Unfortunately 50% of them refuse to receive the necessary treatment exposing them to increase morbidity.
The SomnuSeal mask can be chosen by more than 60% of newly diagnosed patients in comparison to the current 10% of the most successful masks.
Another very interesting result of the SomnuSeal mask usage is a substantial reduction in required air pressure needed to provide a very good therapeutic result. In fact the SomnuSeal masks line requires only 53% of air pressure that is required by traditional masks. This is a huge difference that has many consequences like more compliance in general and specifically better cardiac output for patients after congestive heart failures that require CPAP treatment.

Clinical trial summary:
The SomnuSeal oral mask is tolerated by otherwise CPAP non compliant patients with OSA.
By Giora Pillar, Adi Segev, Eytan Kurtz.
Feb 2011

Compliance with CPAP is the major limiting factor in treating patients with OSA. Nasal masks may cause skin abrasions or eruptions, mask pressure on the ridge of nose, air leaks (eye discomfort), claustrophobia and nasal stuffiness. The novel SomnuSeal mask (Fig 1) is an oral self-adaptable mask located between the teeth and the lips, ensuring no air leaks or skin abrasions. It is more comfortable, adjusts better to the patient’s specific anatomical structure, and potentially reduces rejection by claustrophobic patients. In a previous study, a mixed sample of 20 patients with OSA had slept with the SomnuSeal oral mask for an average of 1 week. Compliant patients slept for an average of 4.5 hours per night.

Aim: To evaluate the efficacy and compliance/tolerability of the SomnuSeal oral mask for a one month treatment period in otherwise non-compliant (untreated) patients with moderate-severe OSA.

Methods: So far, 35 patients with RDI>20 had tried the mask for one month. In all patients the mask was connected to an AutoPAP machine with a heated humidifier. Efficacy (respiratory indices), convenience (questionnaire) and compliance (usage meter) were monitored in all patients.

Results: Thirty five patients (28 males and 7 females, mean age 56±12 years, BMI 33.7±4.9 Kg/m2, RDI 45±20/h) have tried the treatment so far. Of them, 9 were satisfied and complied well with it (for an average of 26 nights, 4.7 hours per night), 4 struggled with it (used it for an average of 15 nights, 3 hours per night), and 22 could not comply with it. In all patients who slept with it, the efficacy (assessed by residual RDI derived from the CPAP device) was good, with an RDI of less than 5/hour. Interestingly, the required optimal pressure decreased from an average of 9.4cmH2O to 4.7cmH2O.

Conclusions: The SomnuSeal oral interface is effective, and may result in converting non-compliant untreated patients with OSA into well treated ones. In the current study so far, 9 of 35 patients (26%) who were CPAP non-compliant and remained otherwise untreated, were satisfied and well tolerated the SomnuSeal mask, while additional 4 patients (11%) struggled with it and may have ended up being treated. These results are encouraging to offer this mask and reduce the currently high prevalence of CPAP non-compliant untreated patients with OSA.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Discover Medical Devices

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Discover Medical Devices Announces Successful Intermediate Results of its SomnuSeal Trial

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Eran Lavi - DiscoverMedical.com 
+972 522649047 info[.]discovermedical.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Discover Medical Devices securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Discover Medical Devices / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove
GE Healthcare and HeartFlow Announce Global Cardiovascular Collaboration
Insulin Delivery Devices Market Size to Expand at 7% CAGR through 2020 Says PMR
Intubation Market Significant Profits Estimated to be Generated by 2025 Says Persistence Market Research
PMR Releases Report for Next Generation IV Infusion Pumps Market Impact of Existing and Emerging Market 2017-2025
Medical Tapes Market to Reach US$ 2Bn by 2024 Reports PMR
Global Pyrogen Testing Market Value Expected to Increase to US$ 1.37 Billion by 2024 Says PMR
Huber Needles Market Expected to Reach US$ 55M by 2024 According to PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)